Prof Ignacio Gil-Bazo (Catholic University of Valencia, Valencia, Spain), Dr Mariana Brandão (Institut Jules Bordet, Brussels, Belgium), Prof Benjamin Besse (Institut Gustave Roussy, Villejuif, France), and Prof Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain) discuss the latest developments in treating EGFR mutated NSCLC, with a focus on exon 20 mutations.

The panel covers updates from the MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr studies, and also explores treatment options for EGFR mutated NSCLC with exon 20 insertions.

Dr Brandão talks about the safety and antitumour activity of zipalertinib in NSCLC patients with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab. The panel also covers the current treatment landscape of EGFR-mutated NSCLC.